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CX3CL1 (fractalkine) plays an important role in in-
flammation by acting as both chemoattractant and as an
adhesion molecule. As for other chemokines, expression
of CX3CL1 is known to be regulated at the level of tran-
scription and translation. The unique transmembrane
structure of CX3CL1 raises the possibility of additional
functional regulation by altering its abundance at the
cell surface. This could be accomplished in principle by
changes in traffic between subcellular compartments.
To analyze this possibility we examined the subcellular
distribution of CX3CL1 in human ECV-304 cells stably
expressing untagged or green fluorescent protein-
tagged forms of the chemokine. CX3CL1 was present in
two distinct compartments, diffusely on the plasma
membrane and in a punctate juxtanuclear compart-
ment. The latter shared some features with, yet was
distinct from the conventional endocytic pathway and
may represent a specialized recycling subcompartment.
Accordingly, surface CX3CL1 was found to be in dy-
namic equilibrium with the juxtanuclear vesicular com-
partment. Intracellular CX3CL1 co-localized with the
SNARE (soluble N-ethylmaleimide factor attachment
protein receptor) proteins syntaxin-13 and VAMP-3.
Cleavage of VAMP-3 by tetanus toxin or impairment of
syntaxin-13 function by expression of a dominant-nega-
tive allele inhibited the ability of internalized CX3CL1 to
traffic back to the plasma membrane. These data dem-
onstrate the existence of a dynamic, SNARE-mediated
recycling of CX3CL1 from the cell surface to and from an
endomembrane storage compartment. The intracellular
storage depot may serve as a source of the chemokine
that could be rapidly mobilized by stimuli.
Inflammation is marked by the migration of circulating leu-
kocytes into sites of injury. The inflammatory process involves
a series of coordinated interactions between leukocytes and
endothelial or epithelial cells. Central to this sequence of
events are chemokines, a family of low molecular weight pro-
teins that function as attractants of leukocytes bearing the
complementary receptors. When engagement of chemokine re-
ceptors occurs, leukocytes become activated and are induced to
adhere firmly to the inflamed endothelium. These initial steps
culminate in diapedesis of the leukocyte across the endothe-
lium and migration into the injured tissue (1). The local com-
plement of chemokines elaborated by each organ is specific and
varies with the type of inflammation present (1). In addition,
specific subsets of leukocytes bear distinct chemokine recep-
tors. In this manner chemokines and their cognate receptors
confer organ specificity to leukocyte migration and help to
fine-tune the nature of the observed inflammatory response.
One such chemokine, CX3CL1 (fractalkine) and its receptor,
CX3CR1, have been shown to be of central importance in di-
verse inflammatory and infectious disease processes. Inter-
rupting this pathway in vivo has a highly protective effect in
animal models of renal inflammation (2), rejection of trans-
planted organs (3, 4), and atherosclerosis (5, 6). Unlike most
other chemokines, CX3CL1 exists in two forms; as a soluble
chemotactic polypeptide and as a transmembrane chemokine/
mucin hybrid protein. In its soluble form, CX3CL1 acts as a
chemoattractant for leukocytes bearing its unique receptor,
CX3CR1 (7, 8). In the membrane-bound form, the mucin stalk
allows the chemokine domain of CX3CL1 to be efficiently pre-
sented to circulating leukocytes (9, 10). Membrane-associated
CX3CL1 has been shown to mediate multiple steps of the leu-
kocyte adhesion cascade, including capture of circulating leu-
kocytes, either alone or in concert with other adhesion mole-
cules such as VCAM-1 (9, 11). After the initial recruitment
step, CX3CL1 interacts with CX3CR1 to further promote acti-
vation and firm the arrest of monocytes, NK cells, and CD8 T
lymphocytes (9). Thus, CX3CL1 has dual roles as a chemoat-
tractant and a cellular adhesion molecule.
Like other chemokines, CX3CL1 biosynthesis is regulated at
the transcriptional and translational levels (7, 9, 12–14). How-
ever, because of its unique transmembrane disposition,
CX3CL1 activity may be controlled by additional mechanisms.
Indeed, it is conceivable that the surface exposure of the mem-
brane-associated chemokine is regulated by traffic between
subcellular compartments, as has been reported for a variety of
membrane receptors and transporters (15–19). Remarkably,
very little is known about the subcellular distribution and
traffic of CX3CL1.
The objective of the present study was, therefore, to charac-
terize the subcellular distribution of CX3CL1, its ability to
translocate between cellular compartments, and the molecular
determinants of this traffic. We found that CX3CL1 actively
cycles between the plasma membrane and an internal, vesicu-
lar pool and also characterized the soluble N-ethylmaleimide
factor attachment protein receptors (SNARE)1 proteins in-
volved in this process. The implications of these findings for the
regulation of CX3CL1 function are discussed.
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EXPERIMENTAL PROCEDURES
Reagents and Antibodies—The following antibodies were used: goat
polyclonal anti-CX3CL1 (R&D Systems, Inc., Minneapolis, MN), anti-
CD63 (Caltag Laboratories, Burlingame, CA), anti-GM130 (Transduc-
tion Laboratories, Lexington, KY), Cy3-, peroxidase-, and Alexa 488-
conjugated anti-goat IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA; Molecular Probes, Inc., Eugene, OR), and Fab frag-
ment of fluorescein isothiocyanate-conjugated anti-goat IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA).
Rhodamine-conjugated transferrin and nigericin were obtained from
Molecular Probes, and colchicine, brefeldin, and o-phenylenediamine
dihydrochloride were from Sigma. DNA expression constructs encoding
GFP-tagged VAMP-3, VAMP-2, and syntaxin-13 as well as dominant
negative-syntaxin-13 and mammalian tetanus toxin were generously
provided by Dr. William S. Trimble (The Hospital for Sick Children
Research Institute, Toronto, Ontario) and Dr. R. Scheller (Stanford
University, Stanford, CA) (20–24). ECV-CX3CL1 cells were transiently
transfected with DNA encoding the above GFP-tagged proteins using
FuGENE (Roche Diagnostics), and transfected cells were analyzed 24 h
later. In separate experiments ECV-CX3CL1 cells were transfected with
EGFP alone or in combination with dominant negative-syntaxin-13 or
tetanus toxin at a ratio of 1:10.
Cell Culture—ECV-304 cells were obtained from the American Type
Culture Collection (Manassas, VA), and the generation of CX3CL1-
expressing ECV-304 cells (ECV-CX3CL1) has been previously described
(9). A plasmid encoding CX3CL1-GFP hybrid molecules was generated
by PCR and subsequent ligation of the DNA fragments into pEGFP-N2
(BD Biosciences Clontech). DNA encoding the extracellular and trans-
membrane portions of CX3CL1 was synthesized using primers 5-
CGGGTCGACTCAGCCATGGCTCCGATA and 5-CTGAGGATCCCC-
ACGGGCACCAGGAC and digested with Sal1 and BamH1. These
fragments were ligated together into the pEGFP-N2 expression vector
digested with SalI and BamH1. The nucleotide sequence of both strands
of the new construct (pCX3CL1-GFP) was determined to verify its
identity. ECV-304 cells were grown in Medium 199 (Invitrogen) con-
taining 10% fetal calf serum and transfected by electroporation (Gene
Pulser II, Bio-Rad) and selected in 500 g/ml G418 (Invitrogen).
CX3CL1 expression was determined by flow cytometry. For some ex-
periments ECV-CX3CL1-GFP cells were grown on glass coverslips and
incubated at 37 °C with either colchicine (10 M) or brefeldin A (100 M)
for 30 min.
COS-7 fibroblast cells were obtained from ATCC and transiently
transfected with pCX3CL1-GFP (COS-CX3CL1-GFP) using FuGENE
(Roche Diagnostics) according to the manufacturer’s specifications. Pri-
mary porcine aortic endothelial cells (PAEC), a gift from Dr. Aleksander
Hinek (The Hospital for Sick Children Research Institute, Toronto,
Ontario), were grown in M199 containing 10% fetal calf serum and
transfected with the pCX3CL1-GFP construct by electroporation
(PAEC-CX3CL1-GFP).
Immunofluorescence Staining—ECV-CX3CL1 cells were grown on
glass coverslips, fixed using 4% paraformaldehyde, washed, and
blocked with 5% donkey serum at room temperature for 1 h. Cells were
incubated with anti-CX3CL1 antibody (Ab) (2.5 g/ml) at room temper-
ature for 1 h followed by Alexa 488-conjugated anti-goat IgG. After
washing again, the cells were permeabilized using 0.1% Triton. Cells
were incubated again with anti-CX3CL1 Ab, this time followed by
Cy3-conjugated anti-goat IgG.
In other experiments ECV-CX3CL1-GFP or SNARE-transfected
ECV-CX3CL1 cells were grown on glass coverslips, fixed with 4%
paraformaldehyde, and permeabilized with 0.1% Triton. Cells were
washed and labeled with anti-CX3CL1 Ab (1 g/ml) followed by Cy3-
conjugated anti-goat IgG. Immunofluorescence was examined using a
Leica DMIRE2 microscope and OpenLab software (Improvision Inc.,
Lexington, MA). Co-localization was determined using OpenLab 4.0.2
co-localization software. The degree of co-localization was expressed
using the Pearson’s correlation coefficient (r), as previously described
(25). In some experiments cells were examined by confocal microscopy
using a Zeiss LSM 510 laser scanning confocal microscope with a 100
oil immersion objective and pinhole size 1.00 airy units (26). For some
experiments confocal images were deconvolved by importing the LSM
file into Volocity 3.0.2 and applying the appropriate point spread func-
tion to 95% confidence limit. GFP was examined using conventional
laser excitation lines and filter sets.
Quantitation of CX3CL1 Using Peroxidase-coupled Ab Labeling—To
quantify the fraction of CX3CL1 at the cell surface, cells were grown to
confluence in 24-well plates and fixed, and exposed epitopes were sat-
urated by incubating with anti-CX3CL1 Ab (2.5 g/ml) at 4 °C for 1 h.
To quantify the total amount of CX3CL1 within the cell, cells were fixed
and permeabilized before incubation with anti-CX3CL1 Ab. Cells were
incubated with a blocking solution of 5% donkey serum followed by
secondary peroxidase-coupled anti-goat IgG at room temperature for
1 h. Cells were washed, and the reaction was developed using the
peroxidase substrate, o-phenylenediamine dihydrochloride. The optical
density was read by spectrophotometry at 492 nm.
Endocytosis Assays—ECV-CX3CL1, ECV-CX3CL1-GFP, COS-
CX3CL1-GFP, or primary PAEC-CX3CL1-GFP cells were grown on
glass coverslips and incubated with anti-CX3CL1 Ab at 37 or 4 °C for
1 h. Cells were washed, fixed with 4% paraformaldehyde, and perme-
abilized with 0.1% Triton. Cells were incubated with Cy3-conjugated
anti-goat IgG, washed, and mounted on glass slides using DAKO fluo-
rescent mounting medium (DAKO Corp., Carpinteria, CA). In other
experiments, after a 1-h serum-free period, ECV-CX3CL1-GFP cells
were incubated with transferrin-rhodamine (30 g/ml) at 37 °C for 1 h
before fixing and mounting. In some experiments, after cells were
incubated with anti-CX3CL1 Ab for 1 h, membrane-associated Ab was
removed by acid wash (0.15 M NaCl, 50 mM glycine, 0.1% bovine serum
albumin, pH 2.5) on ice using published methods (27). Cells were
allowed to recover for various time periods, then washed, fixed, and
incubated with Cy3-conjugated secondary Ab. Cell surface immunoflu-
orescence intensity was measured using MetaMorph imaging software
(Universal Imaging Corp., Westchester, PA).
Fluorescence Recovery After Photobleaching (FRAP)—Analysis of
FRAP was performed as previously described (28, 29). Briefly, ECV-
CX3CL1-GFP or PAEC-CX3CL1-GFP cells were incubated in medium
RPMI containing 10% fetal calf serum and 25 mM HEPES (Invitrogen)
and maintained at 37 °C. Live cells were analyzed by confocal micros-
copy as described above using LP505 filter. A 30-milliwatt LASOS
argon laser, set to 25% intensity, was used to irreversibly photobleach
a region encompassing the entire CX3CL1-associated juxtanuclear com-
partment (5-m diameter). For photobleaching, maximal pinhole size
and 100% of set laser intensity were used, whereas 22% intensity was
used for image acquisition. The dwell time per pixel was 1.60 s. The
recovery of fluorescence was measured serially over time at 45-s inter-
vals. Control, non-bleached areas of the plasma membrane of the same
cell were also serially monitored to quantify the amount of bleaching
caused by repeated image acquisition. At the end of each experiment,
cells were imaged to ensure that no significant structural or positional
changes had occurred during the course of the experiment.
Measurement of pH in the Intracellular CX3CL1 Compartment—
ECV-CX3CL1 cells were grown on coverslips and incubated for 2 h with
anti-CX3CL1 Ab at 37 °C. Cells were washed then incubated with
fluorescein isothiocyanate-conjugated Fab-fragment of anti-goat IgG
(20 g/ml) for 2 h at 37 °C. Coverslips were placed in a Leiden chamber
and mounted on the stage of a Leica IRE microscope for ratio determi-
nation of emitted fluorescence at 2 excitation wavelengths, 440 and 490
nm, as previously described (30). Excitation filters and image acquisi-
tion were controlled using a Lambda 10 filter-wheel controller (Sutter
Instrument Company, Novato, CA) driven by the Metafluor software
(Universal Imaging, Westchester, PA). A Dell Optiplex DGX 590 com-
puter was interfaced with a Photometrics CCD camera via a 12-bit
GPIB/IIA board (National Instruments, Foster City, CA). To generate
standard calibration curves of fluorescence ratio versus pH, cells were
perfused with a series of K-rich solutions of known pH, each contain-
ing 5 g/ml nigericin.
RESULTS
The purpose of the initial studies was to examine the sub-
cellular distribution and traffic of CX3CL1. Endogenous levels
of CX3CL1 in primary cells are difficult to detect using cur-
rently available Ab. In light of this, we adopted another ap-
proach, namely expressing full-length CX3CL1 or GFP-tagged
CX3CL1 in ECV-304 cells, a cell line with epithelial and endo-
thelial characteristics (31, 32). In a previous study cell surface
levels of CX3CL1 on CX3CL1-expressing ECV-304 cells (ECV-
CX3CL1) have been shown to approximate those of primary
human vascular endothelial cells, minimizing the risk of
mistargeting due to overexpression (9).
CX3CL1 Is Expressed in Dual Locations within the Cell—
ECV-CX3CL1 cells were fixed and labeled with an Ab directed
against the extracellular domain of CX3CL1. As expected, the
Ab labeled only the surface of intact cells, as determined using
both conventional epifluorescence (Fig. 1A) and confocal mi-
Recycling of CX3CL1 19859
croscopy (Fig. 1C). To assess whether CX3CL1 is also present
intracellularly, the same cells were then permeabilized and
labeled again with anti-CX3CL1 Ab followed by incubation with
a different secondary Ab. Permeabilization revealed a sizable
intracellular pool of CX3CL1 with juxtanuclear location (epif-
luorescence microscopy, Fig. 1B; confocal microscopy, Fig. 1D).
The relative magnitude of the surface and endomembrane com-
partments was quantified using a spectroscopic immunoperoxi-
dase labeling method (see “Experimental Procedures”). The
plasmalemmal component of CX3CL1 was found to account for
FIG. 2. Identification of the jux-
tanuclear CX3CL1-containing com-
partment. ECV-CX3CL1-GFP cells were
fixed, permeabilized, and incubated with
Ab recognizing the lysosomal marker
CD63 (A) or the Golgi marker GM130 (G).
In other experiments cells were incubated
with transferrin-rhodamine at 37 °C for
1 h (D). In parallel experiments cells were
treated with colchicine before incubation
with anti-CD63 Ab (B) or transferrin-rho-
damine (E). H, cells were treated with
brefeldin A before labeling with anti-
GM130 Ab. C, F, and I, the degree of
co-localization within the regions indi-
cated by the dotted lines in B, E, and H
was determined using OpenLab 4.0.2 co-
localization software (C, co-localization
between CX3CL1-GFP and CD63/Cy3; F,
co-localization between CX3CL1-GFP and
transferrin-rhodamine; I, co-localization
between CX3CL1-GFP and GM130/Cy3).
Large panel insets in B and H represent a
magnified view of the areas indicated by
the dotted lines.
FIG. 1. CX3CL1 is expressed in two distinct subcellular locations. A, ECV-CX3CL1 cells were fixed before labeling with anti-CX3CL1 Ab
and Alexa 488-conjugated secondary Ab. B, the same cells were then permeabilized, incubated again with anti-CX3CL1 Ab, washed, then labeled
with Cy3-conjugated secondary Ab. This allowed the separate visualization of intracellular and cell-surface CX3CL1. C, confocal image of cell which
was fixed but not permeabilized before labeling with anti-CX3CL1 Ab. D, confocal image of a cell that was both fixed and permeabilized before
labeling with anti-CX3CL1 Ab. E–H, ECV-CX3CL1-GFP cells were fixed, permeabilized, and labeled with anti-CX3CL1 Ab. The cellular distribution
of Ab-labeled CX3CL1 (F) was compared with that of GFP-tagged CX3CL1 (E). G, merged image of E and F. H, the degree of overlap of the region
indicated by the dotted line in G was determined using OpenLab 4.0.2 co-localization software and quantitated using the Pearson’s correlation
coefficient (r). I, to confirm the existence of separate subcellular and plasma membrane CX3CL1 expression, cross-sectional images of ECV-
CX3CL1-GFP cells were obtained using confocal microscopy. J, to determine whether intracellular CX3CL1 is associated with microtubules,
ECV-CX3CL1-GFP cells were incubated with colchicine, fixed, and examined by confocal microscopy.
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57  6% of the total cellular pool of CX3CL1.
The existence of CX3CL1 in at least two distinct cellular
compartments was verified in cells expressing GFP-tagged
CX3CL1 (ECV-CX3CL1-GFP). In this construct GFP is at-
tached to the cytosolic tail of the transmembrane chemokine.
The fact that the tagged construct (Fig. 1E) was recognized by
the antibody directed to the extracellular domain anti-CX3CL1
Ab (Fig. 1F) confirms that the expressed protein traverses the
membrane. The presence of GFP and antibody fluorescence at
the surface and in the juxtanuclear endomembrane vesicles
implies that the full-length transmembrane protein is found in
both locations (Fig. 1, G and H). The similarity of this distri-
bution to that of the untagged protein indicates that linkage to
GFP did not visibly alter the cellular targeting of CX3CL1.
We also used confocal microscopy to verify that GFP-tagged
CX3CL1 is indeed expressed in dual locations. As shown in Fig.
1I, cross-sectional analysis confirmed that CX3CL1-GFP is ex-
pressed not only in the plasma membrane but also within a
juxtanuclear compartment. The endomembrane compartment
appears to be maintained in its juxtanuclear location by micro-
tubules, since treatment with colchicine caused the intracellu-
lar CX3CL1-GFP to disperse (Fig. 1J). Interestingly, treatment
with colchicine also caused an appreciable decrease in plasma
membrane CX3CL1-GFP signal. These data raise the possibil-
ity that cell surface CX3CL1 is in dynamic exchange with the
pool of intracellular CX3CL1 and that this exchange relies on
intact microtubules.
Identification of the Juxtanuclear CX3CL1-associated Com-
partment—The identity and function of the intracellular
CX3CL1 compartment were investigated next. We initially as-
sessed whether CX3CL1 was located in lysosomes, recycling
endosomes, or the Golgi apparatus, all of which are maintained
in a juxtanuclear position by retrograde transport along micro-
tubules. ECV-CX3CL1-GFP cells were labeled with a late en-
dosomal/lysosomal marker, anti-CD63 Ab (Fig. 2A). As ex-
pected, some degree of co-localization was detected in the
juxtanuclear region. To obviate the possibility that overlap was
fortuitous, due to the presence of multiple organelles in the
same general region, cells were treated with colchicine before
staining (Fig. 2B). Under these conditions no significant degree
of association between CD63 and the CX3CL1-containing ves-
icles was observed (Fig. 2, B and C; Pearson’s colocalization
coefficient r  0.317  0.041; p  0.1), demonstrating that the
latter compartment does not correspond to late endosomes/
lysosomes.
To investigate whether the intracellular CX3CL1 compart-
ment is associated with recycling endosomes, ECV-CX3CL1-
GFP cells were incubated with rhodamine-conjugated trans-
ferrin for 1 h at 37 °C with (Fig. 2E) or without (Fig. 2D)
colchicine treatment. As shown in Fig. 2D, transferrin was
indeed internalized to a juxtanuclear location resembling that
of CX3CL1. However, when the organelles were dispersed by
microtubule disruption, only partial overlap was observed (Fig.
2, E and F), yielding Pearson’s correlation coefficient slightly
greater than 0.5, which is statistically significant (r  0.515 
0.071; p  0.05) and indicative of partial colocalization. Thus,
the intracellular CX3CL1-containing compartment overlaps
with but is not entirely identical to the transferrin receptor-
containing recycling endosomes.
In similar experiments CX3CL1-containing vesicles were
found to be distinct from the Golgi stacks, identified using
anti-GM130 Ab (Fig. 2, G–I). A dissociation between the two
compartments was also noted when the cells were pretreated
with brefeldin (Fig. 2H; r  0.322  0.068; p  0.1), which is
known to disperse the Golgi cisternae while compacting both
recycling endosomes and the trans-Golgi network. A sizable
fraction of CX3CL1 remained compacted near the nucleus, con-
sistent with location in recycling endosomes and/or trans-Golgi
network. Collectively, these data demonstrate that CX3CL1 is
expressed within a specialized juxtanuclear compartment that
is distinct from late endosomes/lysosomes and Golgi cisternae
but which partially co-localizes with transferrin receptor-asso-
ciated recycling endosomes.
SNARE Proteins in the Intracellular CX3CL1 Compart-
ment—To further characterize the intracellular CX3CL1 com-
partment and to investigate its possible relationship with the
plasmalemmal pool, we proceeded to study molecular entities
that might mediate fusion of CX3CL1-bearing vesicles with the
plasma membrane. The SNARE family of proteins is thought to
mediate the docking and fusion of vesicles with their target
membranes, thereby facilitating the delivery of cargo between
compartments. In an attempt to identify SNARE proteins,
ECV-CX3CL1 cells were transiently transfected with DNA con-
FIG. 3. Co-localization of intracellular CX3CL1 with SNARE
proteins implicated in recycling of plasma membrane proteins.
ECV-CX3CL1 cells were transfected with cDNA for GFP-tagged syn-
taxin-13 (A and B), VAMP-3 (C and D), or VAMP-2 (E and F). To obviate
any fortuitous overlap, cells were also treated with colchicine then
fixed, permeabilized, and labeled with anti-CX3CL1 Ab and Cy3-conju-
gated secondary Ab. The distribution of each GFP-tagged SNARE pro-
tein was compared with that of CX3CL1 in the same cell (A and B,
syntaxin-13; C and D, VAMP-3; E and F, VAMP-2). The degree of
co-localization within the regions indicated by the dotted lines in A, C,
and E was determined using OpenLab 4.0.2 co-localization software (B,
co-localization between CX3CL1/Cy3 and syntaxin-13/GFP; D, co-local-
ization between CX3CL1/Cy3 and VAMP-3-GFP; F, co-localization be-
tween CX3CL1/Cy3 and VAMP-2/GFP). Large panel insets in A and C
and E represent a magnified view of the areas indicated by the dotted
lines.
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structs encoding VAMP-2-GFP, VAMP-3-GFP, or syntaxin-13-
GFP, which are known components of the endocytic and recy-
cling pathway. Cells were fixed, permeabilized, and
immunostained with anti-CX3CL1 Ab to determine possible
co-localization. As before, fortuitous overlap was minimized by
pretreating the cells with colchicine. As illustrated in Fig. 3,
the intracellular CX3CL1 compartment partially co-localized
with syntaxin-13 (Fig. 3, A and B; r  0.632  0.032; p  0.01)
as well as with VAMP-3 (Fig. 3, C and D; r  0.793  0.009; p 
0.01). No significant co-localization with VAMP-2 was observed
(Fig. 3, E and F; r  0.395  0.033; p  0.1). These data support
the notion that intracellular CX3CL1 represents a subcompart-
ment of recycling endosomes and suggest that recycling may
occur by SNARE-mediated fusion of endosomal and plasmale-
mmal membranes.
Plasma Membrane CX3CL1 Undergoes Endocytosis in Di-
verse Cell Types—To ensure that the dual localization of
CX3CL1 is not an idiosyncratic feature of ECV-304 cells, we
transfected the tagged CX3CL1 in other cell types known to
express the chemokine, namely primary porcine aortic endo-
thelial cells and fibroblastic cells (COS-7). In both of these cell
types, CX3CL1 was expressed with a distribution similar to
that seen in ECV cells, namely, on the plasma membrane as
well as in an intracellular location (see Fig. 4).
The results from the preceding experiments suggested that
intracellular CX3CL1 may represent a recycling endosomal
pool. To verify this prediction, we incubated ECV-CX3CL1-
GFP, COS-CX3CL1-GFP, and PAEC-CX3CL1-GFP cells with
an Ab directed to the exofacial domain of CX3CL1 for 2 h at
37 °C. The cells were washed, fixed, and permeabilized before
incubating with secondary Ab. In all three cell types tagged
CX3CL1 was seen to accumulate in the juxtanuclear location in
a time-dependent fashion (Fig. 4, C, D, G, H, K, and L), pro-
viding evidence of dynamic exchange between compartments.
Labeling of the juxtanuclear pool was prevented when the
experiment was performed at 4 °C. In this instance only the
superficial CX3CL1 was labeled (Fig. 4, A, B, E, F, I, and J),
implying that endocytosis is required to deliver the antibody to
the intracellular pool.
Recovery of Fluorescence after Photobleaching of the CX3CL1-
containing Juxtanuclear Compartment—Because Fab frag-
ments of anti-CX3CL1 are not available, the preceding experi-
ments utilized bivalent antibodies to tag CX3CL1. It is,
therefore, conceivable that the observed internalization is not a
constitutive phenomenon but was instead induced by cross-
linking caused by the antibodies. Indeed, traffic of several
proteins is known to be altered by their clustering.
To circumvent this problem, we used a second, complemen-
tary approach, based on FRAP. We took advantage of the
fluorescence of the CX3CL1-GFP chimera to monitor the re-
plenishment of the juxtanuclear pool after elimination of its
fluorescence by photobleaching. Briefly, a region near the cen-
ter of the cell (5 m diameter) encompassing the entire jux-
tanuclear CX3CL1-GFP compartment was irreversibly photo-
bleached using an intense laser beam, and the recovery of
fluorescence was monitored over time (Fig. 5, A–C). The fluo-
rescence of the plasma membrane pool, which remained largely
unaffected by the bleaching procedure, was also monitored. Fig.
5A depicts an ECV-CX3CL1-GFP cell before bleaching, and Fig.
5, B and C, illustrate the same cell immediately after and 5 min
after bleaching, respectively. Note that the plasmalemmal flu-
orescence decreased as the juxtanuclear fluorescence recov-
ered, consistent with delivery of unbleached CX3CL1-GFP from
the former to the latter compartment. The rate of recovery of
endomembrane fluorescence was quantified, and a typical ex-
periment is illustrated in Fig. 5D. In four similar experiments,
FIG. 4. Cell surface CX3CL1 is internalized in diverse cell types. A and B, at 4 °C, ECV-CX3CL1-GFP cells were incubated with
anti-CX3CL1 Ab, then fixed, permeabilized, and incubated with Cy3-conjugated secondary Ab. Because recycling cannot occur at 4 °C, anti-CX3CL1
Ab labeled only the surface of cells (B) but not the internal CX3CL1-GFP-containing compartment (A). C and D, similar experiments were
performed at 37 °C to allow endocytosis to occur. At 37 °C Ab-labeled CX3CL1 was internalized (D) and co-localized with the internal CX3CL1-
GFP-containing compartment (C). E–H, to confirm that endocytosis of plasma membrane CX3CL1 was not unique to ECV-304 cells, similar
experiments were performed using GFP-tagged CX3CL1-expressing COS-7 fibroblasts (COS-CX3CL1-GFP). At 4 °C, anti-CX3CL1 Ab labeled only
the surface of cells (F) but not the internal CX3CL1-GFP-containing compartment (E). At 37 °C, Ab-labeled CX3CL1 was internalized (H) and
co-localized with the internal CX3CL1-GFP-containing compartment (G). I–L, similar experiments were conducted using primary porcine aortic
endothelial cells that expressed GFP-tagged CX3CL1 (PAEC-CX3CL1-GFP). At 4 °C, anti-CX3CL1 Ab labeled only the surface of PAEC-CX3CL1-
GFP (J) but not the internal CX3CL1-GFP-containing compartment (I). At 37 °C, Ab-bound CX3CL1 was internalized (L) and co-localized with the
internal CX3CL1-GFP-containing compartment (K).
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the juxtanuclear CX3CL1-GFP compartment recovered 44 
9% of its original fluorescence, with half-maximal recovery
occurring by 208  72 s. These experiments confirm the exist-
ence of a constitutive recycling of CX3CL1 between the surface
and internal compartments, with a half-life of 	3.5 min. To
further confirm the ability of CX3CL1 to recycle in primary
vascular endothelial cells, we examined FRAP after photo-
bleaching the juxtanuclear compartment in PAEC-CX3CL1-
GFP. In 6 similar experiments, the juxtanuclear CX3CL1-GFP
compartment recovered 43  5% of its original fluorescence,
with half-maximal recovery occurring by 78  2 s (data not
shown). These data demonstrate that CX3CL1 recycles not only
in transformed cell lines but also in primary vascular endothe-
lial cells.
The Intracellular CX3CL1-associated Compartment Is Mod-
erately Acidic—Different subcompartments of the endocytic
and secretory pathways have distinctive luminal pH values
(30, 33–35). To better characterize the internal CX3CL1 com-
partment, we measured its internal pH. The ability of CX3CL1
to continuously cycle between the surface and internal com-
partments (see “Results”) was harnessed to label the endomem-
brane CX3CL1 compartment with a pH-sensitive fluorescent
probe, as illustrated by the diagram in Fig. 6A. An antibody
directed to the exofacial domain of CX3CL1 was tagged with a
fluorescein isothiocyanate-conjugated Fab fragment and al-
lowed to bind to the plasmalemmal chemokine. Over time,
tagged CX3CL1 accumulated in the juxtanuclear location (Fig.
6, B and C). The ratio of emitted fluorescence when cells were
excited at 440 and 490 nm was measured to provide a concen-
tration- and photobleaching-independent measure of compart-
mental pH. Absolute pH values were obtained by comparison to
an internal standard calibration curve (Fig. 6D), obtained in
situ using ionophores. The mean pH of the intracellular
CX3CL1 compartment was found to be 6.3  0.2. This moder-
ately acidic pH is similar to that of recycling endosomes (30)
and differs from the neutral pH of the endoplasmic reticulum
and the much more acidic pH of lysosomes and secretory
granules (30, 33, 35, 36).
Internalized CX3CL1 Cycles Back to the Plasma Membrane—
The preceding experiments show that CX3CL1 can translocate
from the plasmalemma to the endomembrane compartment. At
steady state, one would predict that an equivalent exocytic
delivery of the chemokine would exist to maintain a constant
amount of CX3CL1 at the surface. To validate this notion, the
endomembrane pool was first loaded by incubation with anti-
CX3CL1 Ab at 37 °C for 1 h. Bound Ab remaining at the cell
surface was then acutely removed by briefly stripping with an
FIG. 5. CX3CL1 is internalized from the cell surface. To confirm
that cell surface CX3CL1 recycles, FRAP was performed as described
under “Experimental Procedures.” Using an argon laser and a scanning
confocal microscope, the juxtanuclear CX3CL1-containing compartment
was irreversibly photobleached (arrows), and recovery of fluorescence
was determined at 45-s intervals. A represents ECV-CX3CL1-GFP cell
before bleaching, B depicts the same cell immediately after photo-
bleaching, and C depicts the cell 5 min later. Control areas of the same
diameter in the plasma membrane were examined at each time point.
D, at each time point the ratio of the fluorescence intensity of the
internal compartment to the mean control membrane fluorescence in-
tensity was calculated. Recovery of fluorescence intensity of the jux-
tanuclear compartment for 1 of 4 similar experiments.
FIG. 6. The juxtanuclear CX3CL1-containing compartment is
moderately acidic. A, ECV-CX3CL1 cells were grown on coverslips
and incubated with anti-CX3CL1 Ab and a fluorescein isothiocyanate
(FITC)-conjugated Fab fragment of anti-goat IgG at 37 °C, as described
under “Experimental Procedures.” Shown are a Nomarski image (B)
and immunofluorescent image (C) of cells labeled as described. The
ratio of emitted fluorescence at excitation wavelengths 440 and 490 nm
was determined and compared with standard calibration curves, as
described under “Experimental Procedures.” D, standard curve (closed
diamonds) and juxtanuclear CX3CL1 fluorescence intensity ratio (open
diamonds) for the average of four experiments. FKN, fractalkine.
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acidic solution. The cells were then incubated further, and the
reinsertion of CX3CL1 in the plasma membrane was followed
by quantifying the reappearance of the antibody, labeling with
a secondary Ab, and quantifying cell surface immunofluores-
cence. As shown in Fig. 7, fluorescence at the surface increased
progressively after acid stripping, confirming the occurrence of
exocytosis of CX3CL1 from the endomembrane compartment.
Thus, the chemokine indeed recycles actively between the su-
perficial and internal compartments.
Functional Inhibition of VAMP-3 and Syntaxin-13 Inhibits
Cycling of Internalized CX3CL1 Back to the Plasma Mem-
brane—Because intracellular CX3CL1 co-localizes with
SNARE proteins known to mediate recycling, we next sought to
determine whether functional inhibition of such proteins would
alter traffic of CX3CL1. To this end, ECV-CX3CL1 cells were
transfected with either mammalian tetanus toxin, known to
selectively cleave VAMP-3 and thereby inhibit its function, or
with a dominant negative allele of syntaxin-13 (syntaxin-13-
DN). In each case, cells were co-transfected with EGFP to allow
identification of transfected cells. Exocytic delivery of CX3CL1
was determined using the pre-loading and acid-stripping pro-
tocol described above. Cells were allowed to recover for various
time periods then fixed and incubated with a Cy3-conjugated
secondary Ab for quantitation of CX3CL1 delivery to the sur-
face. As illustrated in Fig. 8, A–F, recycling of internalized
CX3CL1 to the surface of the cells was severely impaired by
tetanus toxin as well as by the dominant negative truncated
form of syntaxin-13 compared with cells transfected with only
EGFP. For cells transfected with EGFP alone, cell surface
fluorescence intensity recovered from 25  1 to 57  5 by 30
min. In comparison, for cells expressing syntaxin-13-DN, fluo-
rescence intensity recovered from 31  2 to 35  1. Surface
fluorescence intensity of cells transfected with tetanus toxin
recovered from 31  1 to 37  2. Overall, in four experiments
dominant negative syntaxin-13 depressed recycling by 86%,
whereas tetanus toxin effected a 82% decrease (Fig. 8G).
DISCUSSION
The principal aim of this study was to investigate the sub-
cellular distribution and traffic of CX3CL1 within cells. For
some of these experiments we used ECV-304 cells transfected
with either untagged or GFP-conjugated CX3CL1. ECV-304
cells were initially described as a spontaneously immortalized
derivative of human endothelial cells (37). Indeed, ECV-304
cells retain several endothelial characteristics, including the
tendency to grow as monolayers of flattened cells, typical of
endothelium (37–39), and expression of the endothelial mark-
ers Flt-1 and von Willebrand factor (40, 41). However, more
recently it has become apparent that the ECV-304 line is in fact
derived from cancerous bladder epithelial cells and is closely
related to the T-24 line (40, 41). Accordingly, ECV-304 cells
grown in monolayers target E-cadherin to the basolateral sur-
face and hemagglutinin from influenza virus to the apical sur-
face (32) and separate these domains by junctions with reduced
permeability to inulin. Yet, these junctions are not as “tight” as
those seen in other epithelial monolayers (32). Thus, it appears
that ECV-304 cells have a phenotype that is intermediate be-
tween endothelial and epithelial cells. In any event, they are a
useful model to study cellular CX3CL1 distribution and traffic
inasmuch as this chemokine is endogenously expressed by both
endothelial and epithelial cells (4, 9, 14, 42). To ensure that the
observed trafficking of CX3CL1 was not an idiosyncratic fea-
ture of transfected ECV-304 cells, we further confirmed our
findings in other cell types known to express CX3CL1, namely
fibroblasts (43) and, especially, primary arterial endothelial
cells (5, 6, 9, 12, 44).
CX3CL1 is synthesized as a 50–75-kDa precursor that is
rapidly processed, presumably glycosylated, yielding the ma-
ture 100-kDa species (45). The mature form can be cleaved
from the cell surface to yield a soluble 85-kDa fragment encom-
passing the majority of the ectodomain (45). Cleavage of
CX3CL1 proceeds both constitutively and inducibly. Constitu-
tive cleavage occurs at low levels and is mediated by the met-
FIG. 7. Internalized CX3CL1 traffics
back to the plasma membrane. ECV-
CX3CL1 cells were incubated with anti-
CX3CL1 Ab at 37 °C for 1 h, then mem-
brane-associated Ab was removed by acid
wash (pH 2.5) at 4 °C. Cells were allowed
to recover for the indicated time period,
then washed, fixed, and incubated with
Cy3-conjugated secondary Ab. Shown are
an immunofluorescent image of mem-
brane-associated anti-CX3CL1 Ab label-
ing (A) and Nomarski image (E) of cells
before acid-stripping. Shown are an im-
munofluorescent image of membrane-
associated anti-CX3CL1 Ab labeling (B)
and Nomarski image (F) of cells immedi-
ately after acid-stripping. Also shown are
an immunofluorescent image (C) and No-
marski image (G) of cells 30 min after
recovering from acid shock. An immun-
ofluorescent image (D) and Nomarski im-
age of cells (H) 90 min after recovering
from acid shock is shown. I, cell surface
immunofluorescence was quantitated us-
ing MetaMorph Imaging Software. Re-
sults represent mean values of 64–72
fields per treatment condition. *, p 
0.0001 versus acid at 0 min.
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alloprotease, ADAM-10 (46). Through the actions of the prote-
ase, tumor necrosis factor-converting enzyme (TACE) (45, 47),
CX3CL1 can be rapidly shed from the cell surface after cell
stimulation with inflammatory agents such as LPS, IL-1 or
phorbol esters (13, 45, 47). Knowledge regarding these proteo-
lytic events is fairly rudimentary. In particular, the subcellular
distribution and mode of activation of TACE and the location of
CX3CL1 at the time of degradation are not well characterized.
A major finding of this study is that CX3CL1 is expressed in
dual locations within the cell; at the plasma membrane as well
as in an intracellular compartment. This pattern of expression
was observed in several cell types, including CX3CL1-express-
ing ECV-304 cells, COS-7 fibroblasts, and primary porcine
aortic endothelial cells. We were further able to demonstrate
that plasma membrane CX3CL1 actively recycles between
these two compartments. The endomembrane compartment
where CX3CL1 resides appears to share some features with
early/recycling endosomes, but the two compartments are not
identical. Thus, the endosomal markers VAMP-3 and syn-
taxin-13 showed significant co-localization with CX3CL1. More-
over, the compartment occupied by CX3CL1 was determined to
have a luminal pH of 6.3, similar to that of early/recycling
endosomes (30). Last, the CX3CL1 compartment collapsed near
the nucleus upon addition of brefeldin A, as is known to be the
case for recycling endosomes.
In our studies the overlap of CX3CL1 with transferrin recep-
tors was imperfect, suggesting that they only partially occupy a
common compartment. These data are consistent with reports
in the literature that support the existence of distinct subcom-
partments within the recycling vesicular pool and with the fact
that transferrin receptors are also found elsewhere. Internal-
ized transferrin accumulates within early endosomes contain-
ing early endosomal antigen 1 (48) and the small GTPase, Rab4
(49, 50). With time, transferrin accumulates within a second
endosomal fraction that is devoid of Rab4 (49) and endosomal
antigen 1 but which contains Rab11 (48). Recent studies have
further clarified the role of Rab11 in protein recycling. Unlike
Rab4, Rab11-containing vesicles can associate with the Sec15
exocyst subunit and fuse with the plasma membrane in exocy-
tosis (51, 52). In our studies a significant portion of CX3CL1 did
not co-localize with transferrin receptor. It is conceivable that
CX3CL1 resides in a distinct, specialized recycling subcompart-
ment, as has been described for the GLUT-4 glucose transport-
ers and for proton pumps in certain specialized tissues (53–56).
Our studies also provide initial information of the molecular
mechanisms involved in CX3CL1 recycling. The functional im-
plication of VAMP-3 and syntaxin-13 in recycling of CX3CL1
may serve in future studies to modulate the biological effects of
the chemokine.
Recycling of CX3CL1 was found to occur constitutively in
unstimulated cells, including both immortalized cell lines and
primary endothelial cells. The significance of this basal recy-
cling is not clear, but it may serve to expose CX3CL1 to a
subpopulation of TACE. In a recent study, endogenous TACE
in COS-7 cells was reported to localize predominantly in a
perinuclear location, with smaller amounts found at the cell
surface and in the endoplasmic reticulum (57). It is, therefore,
possible that a fraction of the cleavage of CX3CL1 occurs intra-
cellularly. In this regard delivery of CX3CL1 to an acidic endo-
membrane compartment may facilitate its fragmentation, since
TACE is known to be synthesized as a proenzyme that is
subsequently activated by furin or a furin-like enzyme (57). Of
note, furin and the related prohormone convertase PC1 have
optimal catalytic activity in moderately acidic environments
(58–60) like that prevailing in the lumen of the recycling
endosomes and trans-Golgi network, where they reside.
It is also possible that the rate of basal recycling of CX3CL1
can be regulated. By accelerating exocytosis, stimuli may mo-
bilize the intracellular storage depot to enhance chemoattrac-
tant release and/or replenish the chemokine associated with
the cell surface. Conversely, stimulation of endocytosis may
represent a means of down-regulating CX3CL1 at the cell sur-
face, with relocation to an internal storage site. The balance
between the net rates of endocytosis and exocytosis coupled
with the rate of cleavage of CX3CL1 from the plasma mem-
brane would collectively determine the net exposure of CX3CL1
at the cell surface. Of interest, regulated recycling of mem-
brane proteins located in specialized recycling compartments,
such as aquaporin-2 and GLUT-4, is key to controlling their
function. Thus, regulation of water reabsorption in the kidney
and of glucose uptake by adipocytes and myocytes depends
critically on membrane traffic (61–63). Further work will be
needed to ascertain if and how inflammatory stimuli influence
the spontaneous rate of CX3CL1 recycling.
FIG. 8. Functional inhibition of syntaxin-13 and VAMP-3 inhib-
its cycling of internalized CX3CL1 back to the plasma mem-
brane. A–F, ECV-CX3CL1 cells were transfected with EGFP alone (A
and D), a dominant negative allele of syntaxin-13 (syntaxin-13-DN; B
and E), or with mammalian tetanus toxin (C and F). Cells transfected
with the syntaxin-13-DN and mammalian tetanus toxin constructs
were co-transfected with EGFP at 1:10 to allow identification of trans-
fected cells (dotted lines). Exocytic delivery of CX3CL1 was determined
using the preloading and acid-stripping protocol described above. Cells
were allowed to recover for 0 or 30 min, then fixed and incubated with
a Cy3-conjugated secondary Ab for quantitation of CX3CL1 delivery to
the surface. The dotted line in D depicts cell surface fluorescence inten-
sity of EGFP-transfected cell indicated in A after a 30-min recovery
period after acid stripping. The dotted line in E depicts cell surface
fluorescence intensity of syntaxin-13-DN/EGFP-expressing cell indi-
cated in B after a 30-min recovery period. The dotted line in F depicts
cell surface fluorescence intensity of tetanus toxin/EGFP-transfected
cell indicated in C after a 30-min recovery period. G, the mean surface
fluorescence intensity of 50 transfected cells per treatment group was
quantitated using MetaMorph Imaging Software by determining the
average pixel number per unit area. The mean recovery of fluorescence
intensity after 30 min was, thus, calculated for 4 separate experiments.
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In summary, we have identified a distinct storage compart-
ment for CX3CL1. Unlike the surface component of CX3CL1,
which functions as a tethering site or a source of chemoattrac-
tant for leukocytes bearing CX3CR1 receptors, the subcellular
compartment may serve as the source for acute up-regulation
of levels of surface CX3CL1. Modulation of the rates of CX3CL1
endocytosis and/or exocytosis could, therefore, provide an al-
ternate means of regulation of chemokine abundance and ac-
cessibility independent of de novo biosynthesis.
Acknowledgments—We thank Dr. Bill Trimble for providing DNA
constructs as well as Cameron Scott, Mauricio Terebiznik, and
Elaine Corbett for expert technical and computer assistance. We are
indebted to Dr. Sergio Grinstein for many helpful discussions and
critical review of the manuscript.
REFERENCES
1. Olson, T., and Ley, K. (2002) Am. J. Physiol. Regul. Integr. Comp. Physiol. 283,
7–28
2. Feng, L., Chen, S., Garcia, G., Xia, Y., Siani, M., Botti, P., Wilson, C., Harrison,
J., and Bacon, K. (1999) Kidney Int. 56, 612–620
3. Haskell, C., Hancock, W., Salant, D., Gao, W., Csizmadia, V., and Peters, W.
(2001) J. Clin. Investig. 108, 679–688
4. Robinson, L., Nataraj, C., Thomas, D., Howell, D., Griffiths, R., Bautch, V.,
Patel, D., Feng, L., and Coffman, T. (2000) J. Immunol. 165, 6067–6072
5. Combadiere, C., Potteaux, S., Gao, J., Esposito, B., Casanova, S., Lee, E.,
Debre, P., Tedgui, A., Murphy, P., and Mallat, Z. (2003) Circulation 107,
1009–1016
6. Lesnik, P., Haskell, C., and Charo, I. (2003) J. Clin. Investig. 111, 333–340
7. Bazan, J., Bacon, K., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D.,
Zlotnick, A., and Schall, T. (1997) Nature 385, 640–644
8. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M.,
Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T., and Yoshie, O. (1997)
Cell 91, 521–530
9. Fong, A., Robinson, L., Steeber, D., Tedder, T., Yoshie, O., Imai, T., and Patel,
D. (1998) J. Exp. Med. 188, 1413–1419
10. Fong, A., Erickson, H., Zachariah, J., Poon, S., Schamberg, N., Imai, T., and
Patel, D. (2000) J. Biol. Chem. 275, 3781–3786
11. Kerfoot, S., Lord, S., Bell, R., Gill, V., Robbins, S., and Kubes, P. (2003) Eur.
J. Immunol. 33, 729–739
12. Harrison, J., Jiang, Y., Wees, E., Salafranca, M., Liang, H., Feng, L., and
Belardinelli, L. (1999) J. Leukocyte Biol. 66, 937–944
13. Ludwig, A., Berkhout, T., Moores, K., Groot, P., and Chapman, G. (2002)
J. Immunol. 168, 604–612
14. Muehlhoefer, A., Saubermann, L., Gu, X., Luedtke-Heckenkamp, K., Xavier,
R., Blumberg, R., Podolsky, D., MacDermott, R., and Reinecker, H. (2000)
J. Immunol. 164, 3368–3376
15. Brown, D. (2003) Am. J. Physiol. Renal Physiol. 284, 893–901
16. Gentzsch, M., Chang, X., Cui, L., Wu, Y., Ozols, V., Choudhury, A., Pagano, R.,
and Riordan, J. (2004) Mol. Biol. Cell 15, 2684–2696
17. Liu, L., Omata, W., Kojima, I., and Shibata, H. (2003) J. Biol. Chem. 278,
30157–30169
18. Sharma, M., Pampinella, F., Nemes, C., Benharouga, M., So, J., Du, K., Bache,
K., Papsin, B., Zerangue, N., Stenmark, H., and Lukacs, G. (2004) J. Cell
Biol. 164, 923–933
19. Zeigerer, A., Lampson, M., Karylowski, O., Sabatini, D., Adesnik, M., Ren, M.,
and McGraw, T. (2002) Mol. Biol. Cell 13, 2421–2435
20. Advani, R., Bae, H.-R., Bock, J., Chao, D., Doung, Y.-C., Prekeris, R., Yoo, J.-S.,
and Scheller, R. (1998) J. Biol. Chem. 273, 10317–10324
21. Chao, D., Hay, J., Winnick, S., Prekeris, R., Klumperman, J., and Scheller, R.
(1999) J. Cell Biol. 144, 869–881
22. Collins, R., Schreiber, A., Grinstein, S., and Trimble, W. (2002) J. Immunol.
169, 3250–3256
23. Huang, X., Kang, Y., Pasyk, E., Sheu, L., Wheeler, M., Trimble, W., Salapatek,
A., and Gaisano, H. (2001) Am. J. Physiol. Cell Physiol. 281, 740–750
24. Randhawa, V., Bilan, P., Khayat, Z., Daneman, N., Liu, Z., Ramlal, T., Vol-
chuk, A., Peng, X., Coppola, T., Regazzi, R., Trimble, W., and Klip, A. (2000)
Mol. Biol. Cell 11, 2403–2417
25. Manders, M., Verbeek, F., and Aten, J. (1993) J. Microsc. (Oxf.) 169, 375–382
26. Terebiznik, M., Vieira, O., Marcus, S., Slade, A., Yip, C., Trimble, W., Meyer,
T., Finlay, B., and Grinstein, S. (2002) Nat. Cell Biol. 4, 766–773
27. van Kerkhof, P., Sachse, M., Klumperman, J., and Strous, G. (2001) J. Biol.
Chem. 276, 3778–3784
28. Lippincott-Schwartz, J., Presley, J., Zaal, K., Hirschberg, K., Miller, C., and
Ellenberg, J. (1999) Methods Cell Biol. 58, 261–281
29. Reits, E., and Neefjes, J. (2001) Nat. Cell Biol. 3, 145–147
30. Touret, N., Furuya, W., Forbes, J., Gros, P., and Grinstein, S. (2003) J. Biol.
Chem. 278, 25548–25557
31. Su, T., Cariappa, R., and Stanley, K. (1999) FEBS Lett. 453, 391–394
32. Haller, C., Kiessling, F., and Kubler, W. (1997) Eur. J. Cell Biol. 75, 353–361
33. Lidell, M., Johansson, M., and Hansson, G. (2003) J. Biol. Chem. 278,
13944–13951
34. Machen, T., Leigh, M., Taylor, C., Kimura, T., Asano, S., and Moore, H. (2003)
Am. J. Physiol. Cell Physiol. 285, 205–214
35. Wu, M., Grabe, M., Adams, S., Tsien, R., Moore, H., and Machen, T. (2001)
J. Biol. Chem. 276, 33027–33035
36. Kim, J., Johannes, L., Goud, B., Antony, C., Lingwood, C., Daneman, R., and
Grinstein, S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2997–3002
37. Takahashi, K., Sawasaki, Y., Hata, J., Mukai, K., and Goto, T. (1990) In Vitro
Cell. Dev. Biol. 25, 265–274
38. Takahashi, K., and Sawasaki, Y. (1992) In Vitro Cell. Dev. Biol. 28, 380–382
39. Hughes, S. (1996) Exp. Cell Res. 225, 171–185
40. Volk, R., Schwartz, J., Li, J., Rosenberg, R., and Simons, M. (1999) J. Biol.
Chem. 274, 24417–24424
41. Kishibe, J., Yamada, S., Okada, Y., Sato, J., Ito, A., Miyazaki, K., and Suga-
hara, K. (2000) J. Biol. Chem. 275, 15321–15329
42. Lucas, A., Chadwick, N., Warren, B., Jewell, D., Gordon, S., Powrie, F., and
Greaves, D. (2001) Am. J. Pathol. 158, 855–866
43. Yoshikawa, M., Nakajima, T., Matsumoto, K., Okada, N., Tsukidate, T., Iida,
M., Otori, N., Haruna, S., Moriyama, H., Imai, T., and Saito, H. (2004)
FEBS Lett. 561, 105–110
44. Umehara, H., Bloom, E., Okazaki, T., Domae, N., and Imai, T. (2001) Trends
Immunol. 22, 602–607
45. Garton, K., Gough, P., Blobel, C., Murphy, G., Greaves, D., Dempsey, P., and
Raines, E. (2001) J. Biol. Chem. 276, 37993–38001
46. Hundhausen, C., Misztela, D., Berkhout, T., Broadway, N., Saftig, P., Reiss,
K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., Kallen, K.-J.,
Rose-John, S., and Ludwig, A. (2003) Blood 102, 1186–1195
47. Tsou, C.-L., Haskell, C., and Charo, I. (2001) J. Biol. Chem. 276, 44622–44626
48. Sheff, D., Pelletier, L., O’Connell, C., Warren, G., and Mellman, I. (2002)
J. Cell Biol. 156, 797–804
49. Daro, E., van der Sluijs, P., Galli, T., and Mellman, I. (1996) Proc. Natl. Acad.
Sci. U. S. A. 18, 9559–9564
50. McCaffrey, M., Bielli, A., Cantalupo, G., Mora, S., Roberti, V., Santillo, M.,
Drummond, F., and Bucci, C. (2001) FEBS Lett. 495, 21–30
51. Ward, E., Martinez, C., Vaccaro, C., Zhou, J., Tang, Q., and Ober, R. (2005)
Mol. Biol. Cell 16, 2028–2038
52. Zhang, X., Ellis, S., Sriratana, A., Mitchell, C., and Rowe, T. (2004) J. Biol.
Chem. 279, 43027–43034
53. Yao, X., and Forte, J. (2003) Annu. Rev. Physiol. 65, 103–131
54. Pastor-Soler, N., Beaulieu, V., Litvin, T., Da Silva, N., Chen, Y., Brown, D.,
Buck, J., Levin, L., and Breton, S. (2003) J. Biol. Chem. 278, 49523–49529
55. Rudich, A., and Klip, A. (2003) Acta Physiol. Scand. 178, 297–308
56. Govers, R., Coster, A., and James, D. (2004) Mol. Cell. Biol. 14, 6456–6466
57. Schlondorff, J., Becherer, J., and Blobel, C. (2000) Biochem. J. 347, 131–138
58. Hatsuzawa, K., Nagahama, M., Takahashi, S., Takada, K., Murakami, K., and
Nakayama, K. (1992) J. Biol. Chem. 267, 16094–16099
59. Stieneke-Grober, A., Vey, M., Angliker, H., Shaw, E., Thomas, G., Roberts, C.,
Klenk, H., and Garten, W. (1992) EMBO J. 11, 2407–2414
60. Zhou, Y., and Lindberg, I. (1993) J. Biol. Chem. 268, 5615–5623
61. Sun, T., Van Hoek, A., Huang, Y., Bouley, R., McLaughlin, M., and Brown, D.
(2002) Am. J. Physiol. Renal Physiol. 282, 998–1011
62. Katsura, T., Ausiello, D., and Brown, D. (1996) Am. J. Physiol. Renal Fluid
Electrolyte Physiol. 270, 548–553
63. Jhun, B., Rampal, A., Liu, H., Lachaal, M., and Jung, C. (1992) J. Biol. Chem.
267, 17710–17715
Recycling of CX3CL119866
